ArticleHemaSphere2026

Longitudinal assessments of MRD in high-risk newly diagnosed transplant-ineligible multiple myeloma in the BENEFIT study (IFM2020-05).

Jill Corre et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.